#South Korea #Seoul #Seegene #CURECA #STAgora

Seegene's Path to Full Automation in Molecular Diagnostics

Seegene Inc., a frontrunner in the field of molecular diagnostics, recently showcased their innovative technologies, CURECA™ and STAgora™, at the ADLM 2025 conference, held in Chicago from July 29 to 31. These advanced systems are set to revolutionize laboratory automation and data monitoring of infectious diseases. Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, emphasized the importance of these developments in achieving a future with minimal diseases.

Pioneering PCR Automation with CURECA™

The introduction of CURECA™ marks a monumental step for the industry as it is the world's first fully autonomous PCR testing automation system. Traditionally, laboratories relied heavily on skilled personnel for manual operations within testing protocols, leading to inefficiencies. CURECA™ aims to eliminate this bottleneck by automating every stage of PCR testing, including the notoriously manual pre-processing stage.

Dr. Chun pointed out that true automation in diagnostics requires meeting three critical conditions: the ability to operate without highly skilled personnel, continuous 24/7 operation, and seamless sample input. CURECA™ is designed to meet all these criteria. Its specialized module, CURECA™ Prep, processes a wide array of sample types—such as urine, blood, sputum, and stool—overcoming significant obstacles to full automation.

This system manages the complete workflow of PCR testing from sample loading to nucleic acid extraction, amplification, and result analysis without the need for manual intervention. The efficiency of CURECA™ minimizes human error and enables laboratories to reallocate skilled personnel to more complex tasks.

Additionally, the versatility of CURECA™ allows it to adapt to different laboratory sizes and workflows, and it holds potential for application in other testing fields, including clinical chemistry and immunodiagnostics.

Real-Time Data Analysis with STAgora™

Alongside CURECA™, Seegene unveiled STAgora™, their latest platform for real-time PCR data analysis. This revolutionary tool is designed to provide laboratories with a comprehensive context for the information yielded by PCR tests. STAgora™ features over 40 analytical tools that facilitate tracking infection trends, monitoring hospital-level positive test results, and analyzing co-infection structures at a multipathogen level.

Rather than serving as a mere data repository, STAgora™ is an integrated platform that helps laboratories derive insightful analytics from test data. Traditional testing often produces isolated results, lacking the broader context needed for meaningful insights. With STAgora™, hospitals can build personalized datasets and compare aggregated data with other institutions, expediting the identification of infection patterns and informing better clinical decisions.

The data transmitted via STAgora™ is anonymized and formatted to meet institutional requirements, ensuring the secure exchange of information at local, national, or global levels.

Commitment to a Disease-Free World

Reflecting on the long-term vision of Seegene, Dr. Chun reiterated the goal of cultivating a “world without diseases.” He emphasized that the launch of CURECA™ and STAgora™ completes the establishment of five key technological pillars of Seegene, which include proprietary PCR technology, Seegene's digital product development system (SGDDS) for automated test development, a global technology exchange initiative, and the new systems for fully automated PCR testing and real-time data analysis.

The reception of these innovations at ADLM 2025 was overwhelmingly positive, with industry experts lauding the CURECA™ platform for its potential to streamline laboratory operations, reduce the burden on staff, and significantly enhance overall operational efficacy. Jamel Giuma, President and CEO of JTG Consulting Group, noted, "Having attended many ADLM conferences, I've found CURECA™ to be one of the most innovative solutions I've encountered. It promises to simplify laboratory workflows dramatically."

Dr. Chun concluded, “With CURECA™ and STAgora™, we are removing long-standing barriers in molecular diagnostics. Like smartphones and electric vehicles transformed their industries, these technologies are poised to redefine what is possible in diagnostic testing, enabling laboratories around the globe to achieve true automation and realize the value of diagnostic data while contributing towards a disease-free world.”

Note: The CURECA™ and STAgora™ systems demonstrated at ADLM 2025 are pre-commercial technologies, currently under development and not yet available for clinical diagnostic use in any jurisdiction.